The White House is preparing to announce a new round of voluntary drug-pricing agreements aimed specifically at what state Medicaid programs pay for prescription drugs, according to reporting that surfaced in the final days of August 2026. The deals would target midsize biotech companies rather than the large drugmakers the administration has already signed, and no agreement has been finalized as of this writing.
A Medicaid-Only Discount Structure
Under the arrangement being discussed, participating companies would agree to price their outpatient drugs for state Medicaid programs in line with what they charge in a basket of high-income foreign countries, extending the administration’s “Most Favored Nation” framework specifically into the Medicaid channel. Lindsay Bealor Greenleaf, who leads market access policy strategy at the consulting firm ADVI, explained the mechanism in comments summarized in a World Pharma Today report: the Medicaid program would receive the lower price on net through a rebate, with the manufacturer effectively sending money back to the government rather than lowering the sticker price paid at the pharmacy counter.
That structure matters for what it does not change. Because the discount flows through a rebate to the state program rather than the point of sale, the deals would not directly affect what a Medicaid enrollee pays out of pocket, since Medicaid’s own cost-sharing rules already keep those amounts low. The financial impact would land squarely on manufacturers and state budgets rather than on individual patients standing at the counter.
Medicaid is not just a program for low-income families. Nearly 12 million people are enrolled in both Medicare and Medicaid, according to a KFF profile of these dual-eligible beneficiaries, and many rely on Medicaid to cover costs Medicare does not, including long-term nursing home care and, in many states, outpatient prescription drugs. A pricing change aimed at Medicaid drug spending would eventually reach that population, even though the announcement being prepared is framed around biotech companies rather than beneficiaries.
The administration has framed this broader push as a response to a well-documented price gap. American patients typically pay far more for brand-name prescription drugs than patients in other high-income countries, in some cases close to three times as much for the same medication, which is the disparity the Most Favored Nation framework is designed to close.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
Seventeen Companies Already in the Program
This would not be the administration’s first such arrangement. Seventeen pharmaceutical companies, including Pfizer, Eli Lilly and Johnson & Johnson, have already signed voluntary Most Favored Nation agreements covering their own drugs, and the administration has said it hopes to eventually reach similar terms with most manufacturers of sole-source brand-name drugs and biologics. One example became public in April 2026, when the White House announced a deal with Regeneron to bring its drugs in line with the same foreign-price benchmark now being discussed for Medicaid.
Companies that sign on are reported to receive incentives in return, including relief from pharmaceutical tariffs and a possible exemption from other Medicare pricing pilots the administration has floated. Those trade-offs have made the voluntary deals more attractive to manufacturers than fighting the administration over pricing policy directly, even though nothing in federal law requires any company to sign one.
Nothing Has Been Signed Yet
As of August 29, 2026, no company has been named as a participant in this specific Medicaid-focused round, and the deal itself has not been finalized. The reporting that surfaced on August 26 said an announcement could come as soon as August 31, but the World Pharma Today account of the story noted the plan “had not been independently verified at the time of reporting” and that key details, including which drugmakers would take part, remained unresolved.
Because these agreements are negotiated directly between the administration and individual drug companies rather than passed as legislation, they do not require a vote in Congress and can be altered or expanded at the administration’s discretion. That also means a company can decline to participate, and previous rounds have moved forward only with manufacturers that chose to sign on voluntarily.
The administration has pointed to its own projections to make the case for expanding the program. In a May 2026 analysis, the White House’s Council of Economic Advisers estimated that extending Most Favored Nation pricing specifically to Medicaid and cash-paying patients could save a combined $64.3 billion in federal and state spending over ten years, with total savings across all U.S. drug markets projected at $529 billion over the same period. Those figures are the administration’s own projection, not an audited outcome, and they predate the midsize biotech deals now being prepared.
For Medicaid enrollees, including many of the dual-eligible beneficiaries described above, the practical effect of any new deal would depend entirely on which drugs and companies end up covered once an agreement is actually signed. Until an announcement is made and specific companies are named, the honest description of where things stand is that the White House is still preparing the deal, not delivering it. The next confirmation to watch for is a formal announcement from the White House itself, not the anonymously sourced reporting that broke the story on August 26.
This article was produced with AI assistance and reviewed by The Financial Wire editorial team.
More Financial Reading
- Adding someone to your bank account: tax traps and smart moves
- What really happens to your joint savings account when you die?
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
